US health watchdog curbs exports from India's Wockhardt

The US health regulator has restricted exports from a plant owned by Indian generic drugmaker Wockhardt in the latest ban on its products, sending the company's shares tumbling 14 percent on Wednesday.

The US Food and Drug Administration slapped an "import alert" on the company's Chikalthana plant in Maharashtra state, the regulator said in a notice on its website late Tuesday.

An "import alert" means "detention without physical examination of drugs" from companies which have failed to meet so-called "good manufacturing practices" for drugs, the FDA said.

Wockhardt shares fell as much as 13.98 percent to a day's low of 406 rupees on the Bombay Stock Exchange on news of the new import restrictions.

The same factory has already been targeted by Britain's health regulator, which last month recalled five drugs made by the firm at the plant.

Wockhardt has faced a string of export restrictions this year at some of its other factories in India. They were imposed by British and US watchdogs, citing manufacturing concerns.

There was no immediate comment from the company.

India's government has defended its lucrative generic drug industry, which accounts for nearly $15 billion in annual exports, as safe and tightly regulated.

India's pharma giant Ranbaxy, after facing a lengthy legal battle in the United States, was hit by a new setback in September.

The US FDA that month banned imports from Ranbaxy's "ultra modern" Mohali plant in northern India, whose renovation was supposed to mark a turning point for the Indian generics giant after years of run-ins with US regulators.

Now three of Ranbaxy's plants have been hit by a ban on exports to the United States, its largest market.

add to favorites email to friend print save as pdf

Related Stories

India's Ranbaxy promises to address issues over US ban

Sep 17, 2013

India's Ranbaxy Laboratories, one of world's biggest generic drug makers, said Tuesday it would take "all necessary steps" to help lift an import ban by the US health regulator on one of its factories.

Ranbaxy taking 'stringent steps' to end US FDA ban

Sep 21, 2013

India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.

India says its drugs safe after generics fraud

Jun 03, 2013

India, known as the "pharmacy to the world", Monday defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

20 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments